Nektar reports $1.02B cash after equity raise, initiates Phase 3 atopic dermatitis trials

Filed August 13, 2026 · Period ending August 13, 2026 · ~1 min read

Key Changes

• high

  Cash and investments reached $1.02B at June 30, 2026, up from $245.8M at year-end 2025, following April 2026 equity offering that raised $373.8M in gross proceeds. Cash runway extends into Q3 2028.

  Exhibit 99.1 view on EDGAR →
• high

  Initiated first two of three planned Phase 3 ZENITH AD trials for rezpegaldesleukin in moderate-to-severe atopic dermatitis in July 2026. Phase 3 alopecia areata study planned for early 2027, with first BLA submission targeted for 2029.

  Exhibit 99.1 view on EDGAR →
• medium

  Q2 2026 net loss of $40.6M ($1.23 per share) versus $41.6M loss ($2.95 per share) in Q2 2025. Revenue declined to $10.1M from $11.2M year-over-year.

  Exhibit 99.1 view on EDGAR →